Ascites News and Research

RSS

Beta-blockers show anti-inflammatory effects in cirrhosis

Approximately 170,000 people die every year in Europe from the direct consequences of advanced chronic liver disease (cirrhosis).

10 Dec 2020

Study could pave the way for potential urine test to diagnose liver fibrosis

Fifty fragments of proteins, termed peptides, have been identified in the urine of liver fibrosis patients in a new study that could pave the way for a potential diagnostic urine test for the condition if further validated.

16 Nov 2020

Study identifies three clinical course variations in patients with acute decompensated cirrhosis

When the body can no longer compensate the gradual failure of the liver caused by liver cirrhosis, there is a high risk of acute decompensated liver cirrhosis.

27 Aug 2020

Researchers identify three forms of disease progression for acute decompensated liver cirrhosis

When the body can no longer compensate the gradual failure of the liver caused by liver cirrhosis, there is a high risk of acute decompensated liver cirrhosis.

26 Aug 2020

Non-invasive algorithm predicts complications in patients following recovery from hepatitis C

The chronic viral inflammation of the liver that occurs in hepatitis C results in the formation of inflexible scar tissue in the form of fibrosis/cirrhosis of the liver. This impedes the flow of blood through the organ, with resulting hypertension in the portal vein.

23 Jul 2020

Experts develop a simple questionnaire to raise awareness about managing liver disease

Alcohol's popularity and its central place in socializing in Australia obscures the dangers of excessive drinking and possible liver disease, Flinders University experts warn.

11 Jul 2020

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

8 Jan 2020

Study finds lower levels of liver decompensation in pregnant women with cirrhosis

Data from a new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation – found that less than two percent of pregnant women with cirrhosis had liver decompensation within one year of delivery, and their odds of decompensation is much lower than non-pregnant women with cirrhosis.

10 Nov 2019

New drug Aliskiren shows promise for heart failure patients

A study published in the International Journal of Molecular Sciences, as part of a special issue “Heart Failure: From Molecular Basis to Therapy”, in August 2019, shows that aliskiren, a drug approved by the US Food and Drug Administration (FDA), can improve survival for over 5 years, on average, and enhance life quality in patients who have been correctly diagnosed with heart failure.

9 Oct 2019

Novel technology makes biopsies less invasive and more informative

A team of researchers from the National University of Singapore has developed a novel technology that could sensitively and accurately detect and classify cancer cells, as well as determine the disease aggressiveness from the least invasive biopsies.

10 Sep 2019

Hypertension drug may improve effectiveness of ovarian cancer treatment

A new study from a Massachusetts General Hospital research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer

16 Jan 2019

Study reveals how molecular mechanisms regulate lysosomal exocytosis by phagocytes

Lysosomes are filled with more than 50 different hydrolytic enzymes, which are capable of digesting most cellular components.

23 Dec 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

A Single Platform to Sequence All Monoclonal Antibody Proteins

Having a single platform to sequence all monoclonal antibody proteins provides researchers with key information for research, development and drug discovery

From Rapid Novor Inc 3 Oct 2018

BIDMC scientists develop new tool to benefit patients with HCV-associated liver failure

An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention.

18 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Study: One-third of bacterial infections in patients with cirrhosis induced by MDR bacteria

A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant bacteria of 34% and significant regional differences in the risk of developing a multi-drug-resistant infection.

13 Apr 2018

Using the Microbiome to Predict the Risk of Cirrhosis-Associated Hospitalization

The microbiome is the collection of microorganisms that colonize the human body. Dr. Jasmohan Bajaj discusses the relationship between the microorganisms in the gut and cirrhosis, and how microbiome analysis can be used to predict the risk of cirrhosis-associated hospitalizations.

7 Apr 2018

Novel oncolytic virus expressing BiTE molecule elicits T cell-mediated killing of tumor cells

In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.

13 Mar 2018

Drinking during late adolescence could be first step to liver problems in adulthood

Alcohol is the leading cause of liver cirrhosis and liver-related deaths. Results of a large long-term study in Sweden have confirmed that drinking during late adolescence could be the first step towards liver problems in adulthood and that guidelines for safe alcohol intake in men might have to be revised downwards, reports the Journal of Hepatology.

22 Jan 2018